Embera NeuroTherapeutics, Inc. is a specialty pharmaceutical company focused on developing treatments for smoking cessation, cocaine dependence and other addictions, for which there are a limited range of effective drug therapies or no approved treatments. Embera is developing an innovative drug combination (EMB-001) targeting the stress response system and specific brain functions that lead to craving and relapse associated with these disorders, an approach based on years of NIH funded research on the role of stress in addiction and potential treaments.
EMB-001 has successfully demonstrated clinical activity in a published pilot clinical study in cocaine-dependent subjects. In addition, efficacy against cocaine, nicotine and methamphetamine dependence has been shown in published preclinical models of addiction.
Embera's preclinical studies in nicotine dependence for EMB-001 demonstrated statistically significant reductions in nicotine self-administration (up to 80% reductions, versus only 50% reductions seen with varenicline (Chantix®). In addition, Embera and its partner, LSU Health – Shreveport, are completing work under a major $3.9 million grant by the National Institute on Drug Abuse (NIDA) to support the EMB-001 cocaine dependence development program. This work will also enable Embera's smoking cessation development program.
Listen to the 2/18/14 episode of BioTech Nation
with host Dr. Moira Gunn. Robert Linke, Embera's CEO, discusses EMB-001 and smoking cessation. Availble via the following YouTube video.